CHICAGO DIVERSIFIED PROJECTS, INC. – Trademark Portfolio
Entity Type: 03
CHICAGO DIVERSIFIED PROJECTS, INC. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include SAFE SEPTIC and MOST TRUSTED. The owner is based in CHICAGO, IL.
6015 N. Ridge
CHICAGO, IL 60660
Showing of trademarks Trademarks
Trademark Classifications
CHICAGO DIVERSIFIED PROJECTS, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does CHICAGO DIVERSIFIED PROJECTS, INC. have?
CHICAGO DIVERSIFIED PROJECTS, INC. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending.
What trademark classes does CHICAGO DIVERSIFIED PROJECTS, INC. file in?
CHICAGO DIVERSIFIED PROJECTS, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are CHICAGO DIVERSIFIED PROJECTS, INC.'s most well-known trademarks?
CHICAGO DIVERSIFIED PROJECTS, INC.'s registered trademark portfolio includes well-known marks such as SAFE SEPTIC and MOST TRUSTED. These are among 2 currently registered trademarks in the portfolio.
What is CHICAGO DIVERSIFIED PROJECTS, INC.'s trademark registration success rate?
CHICAGO DIVERSIFIED PROJECTS, INC. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 1 application is pending review.